阿尔茨海默病防治的挑战与展望  

Prevention and treatment of Alzheimer′s disease:challenges and perspectives

作　　者：卜先乐 孙彬录 王延江 Bu Xianle;Sun Binlu;Wang Yanjiang(Department of Neurology and Centre for Clinical Neuroscience,Daping Hospital,Third Military Medical University,Chongqing 400042,China)

机构地区：[1]陆军军医大学大坪医院(陆军特色医学中心)神经内科,重庆400042

出　　处：《中华神经科杂志》2021年第7期635-639,共5页Chinese Journal of Neurology

基　　金：国家自然科学基金(81625007,81930028);科技部“重大慢性非传染性疾病防控研究”重点专项(2016YFC1306401)。

摘　　要：阿尔茨海默病(AD)是最常见的神经系统退行性疾病,我国乃至全球都面临严峻的发病形势。AD发病机制尚未阐明,缺乏有效防治措施。β-淀粉样蛋白(Aβ)和过度磷酸化的tau蛋白是AD的核心病理物质。过去20年间以Aβ、tau蛋白等为靶点的临床新药试验未能取得改善认知的效果。文中分析当前AD防治面临的困境和原因,并对AD防治研究进行展望。Alzheimer′s disease(AD),the most common neurodegenerative disease,is a major challenge in China and all the world.However,the pathogenesis of AD remains unclear,and no disease-modifying therapies are available to prevent or treat the disease.Amyloid-beta(Aβ)and hyperphosphorylated tau protein are key pathological molecules of AD.A series of clinical trials targeting Aβ,tau protein and neuroinflammation have been carried out in the past 20 years,but none of them have been successful in attenuating the cognitive decline so far.This paper discusses the challenges of the current clinical trials of AD and proposes future directions for the research of AD prevention and treatment.

关 键 词：阿尔茨海默病 Β淀粉样蛋白 TAU蛋白 临床试验 预防 治疗 

分 类 号：R749.16[医药卫生—神经病学与精神病学]